四川省医师协会肿瘤医师分会秘书

四川省医师协会肿瘤医师青委会委员

四川省肿瘤学会基因与免疫治疗分会常委

北京整合医学学会胸部肿瘤转化医学分会委员

整合肿瘤学分会青委会委员

l Yao Z#, Tang M, Jin Y, et al. Successful Pregnancy and Healthy Baby Outcome in a Patient With Tyrosine Kinase Inhibitor-Refractory ALK-Positive NSCLC and Central Nervous System Metastasis Treated With Lorlatinib With Maternal-Fetal Pharmacokinetics and Child Milestone Development Correlations. J Thorac Oncol.  (共同一作，IF=20.8)

l Zheng Y, ect, Yao Z*, Lu Y*. STING Agonist Synergistically Amplifies PD-1 Blockade and Radiation-induced Systemic Anti-tumor Responses via Tumor Microenvironment Enrichment. International Journal of Radiation Oncology • Biology • Physics. 2025. (共同通讯，IF=6.4)

l Liao S#, Kang K#, Yao Z*, Lu Y*. Nervous system contributions to small cell lung cancer: Lessons from diverse oncological studies. Biochim Biophys Acta Rev Cancer. 2025. (共同通讯，IF=9.7)

l Wang H#, Yao Z#, Kang K#, et al. Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer. Med. 2024. (共同一作，IF=12.8)

l Zhou X#,  Zhou L#, Yao Z#, et al. Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1+ Non-Small-Cell Lung Cancer Patients. Clin Cancer Res. 2023. (共同一作，IF=10.4)

l Zhou X#, Yao Z#, Bai H, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncol. 2021. (共同一作，IF=41.6)

l Zhou X#, Yao Z#, Yang H, et al.Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med. 2020. (共同一作，IF=7.1)